Welcome to our dedicated page for PERCHERON THERAPETS S/ADR news (Ticker: ATHJY), a resource for investors and traders seeking the latest updates and insights on PERCHERON THERAPETS S/ADR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PERCHERON THERAPETS S/ADR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PERCHERON THERAPETS S/ADR's position in the market.
Antisense Therapeutics Limited [US OTC: ATHJY] reported promising findings from its collaboration with Dr. Igor Koralnik on Long COVID-19. A study using Somalogic's SomaScan® uncovered novel blood markers potentially useful for diagnosis and treatment. Three provisional patents have been filed in the US to protect these discoveries. Notably, a therapeutic marker modulated by ATL1102, previously tested in other conditions, suggests further exploration into its application for Long COVID-19. The company aims to engage with pharmaceutical partners for commercialization.
Antisense Therapeutics Limited (US OTC: ATHJY) has announced positive results from a study on ATL1102 for limb girdle muscular dystrophy R2 (LGMDR2), highlighting significant reductions in key immune cell RNA levels in a dysferlin-deficient mouse model. The research, conducted in collaboration with the Jain Foundation and MCRI, showed a notable decrease in CD49d RNA and immune cell markers, positioning ATL1102 for further investigation in a planned chronic study. The findings underscore the urgent need for treatment in a condition affecting approximately 1 in 125,000 people, with no current effective therapies available.
